However, brentuximab vedotin, a CD30 targeting antibody-drug conjugate, has demonstrated significant clinical response in variable CD30+ CTCL patients (7, 8). This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.